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Parkinson’s disease (PD) is an age-related neurodegenerative disorder characterized by the slow 
and progressive death of dopaminergic neurons in the (substantia nigra pars compact). Hypericum 
perforatum (H. perforatum) is a plant widely used as an antidepressant, that also presents antioxidant 
and anti-inflammatory properties. We evaluated the effects of H. perforatum on the turning behavior of 
rats submitted to a unilateral administration of 6-hydroxydopamine (6-OHDA) into the medial forebrain 
bundle as an animal model of PD. The animals were treated with H. perforatum (100, 200, or 400 mg/kg, 
v.o.) for 35 consecutive days (from the 28th day before surgery to the 7th day after). The turning behavior 
was evaluated at 7, 14 and 21 days after the surgery, and the turnings were counted as contralateral or 
ipsilateral to the lesion side. All tested doses significantly reduced the number of contralateral turns in 
all days of evaluation, suggesting a neuroprotective effect. However, they were not able to prevent the 
6-OHDA-induced decrease of tyrosine hydroxylase expression in the lesioned striatum. We propose that 
H. perforatum may counteract the overexpression of dopamine receptors on the lesioned striatum as a 
possible mechanism for this effect. The present findings provide new evidence that H. perforatum may 
represent a promising therapeutic tool for PD.
Uniterms: Parkinson’s disease/treatment/experimental study. H. perforatum/phytotherapy/neuroprotective 
effect. Turning behavior. 6-OHDA.
A Doença de Parkinson é uma doença neurodegenerativa relacionada à idade, caracterizada pela morte 
lenta e progressiva de neurônios dopaminérgicos da substância negra pars compacta. O Hypericum 
perforatum (H. perforatum) é um fitoterápico utilizado como antidepressivo, apresentando propriedades 
antioxidantes, anti-inflamatórias e nootrópicas. Neste trabalho, avaliaram-se os efeitos do tratamento 
com H. perforatum no comportamento rotatório de ratos no modelo da doença de Parkinson induzido 
pela administração unilateral de 6-OHDA no feixe prosencefálico medial. Ratos Wistar machos foram 
tratados com H. perforatum (100, 200 ou 400 mg/kg, v.o.) por 35 dias (do 28º dia antes até o 7º dia após 
a lesão). As rotações ipsilaterais e contralaterais à lesão foram registradas no 7º, 14º e 21º dias após 
a cirurgia. As três doses de H. perforatum utilizadas reduziram o número de rotações contralaterais, 
indicando um possível efeito neuroprotetor da planta. Porém, o H. perforatum não impediu a redução na 
expressão da enzima tirosina hidroxilase no estriado lesionado, quantificada por Western blot. Propomos 
que o H. perforatum possa bloquear o aumento da expressão dos receptores dopaminérgicos no estriado 
lesionado com 6-OHDA. Entretanto, estudos adicionais são necessários para identificar o mecanismo 
exato pelo qual o H. perforatum reduziu o número de rotações contralaterais. Os resultados do presente 
estudo sugerem o H. perforatum como um potencial agente terapêutico para a doença de Parkinson.
Unitermos: Doença de Parkinson/tratamento/estudo experimental. H. perforatum/fitoterapia/efeito 
neuroprotetor. Comportamento rotatório. 6-OHDA.
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INTRODUCTION
Parkinson’s disease (PD) is a debilitating disease 
characterized by the progressive loss of dopaminergic 
neurons in the substantia nigra pars compacta (SNpc) 
(Hirsch et al., 1988, 2005). At the time of diagnosis, 
patients typically display variety of motor impairments, 
including bradykinesia, resting tremor, rigidity, and 
postural instability.
Although the etiology of the neurodegenerative 
process found in PD is not completely understood, it 
has been suggested that a state of oxidative imbalance is 
triggered by one or more factors, including brain aging, 
genetic predisposition, mitochondrial dysfunction, free 
radical production and environmental toxins (Henchcliffe, 
Beal, 2008; Zhou, Huang, Przedborski, 2008). Novel 
therapeutic strategies support the application of 
reactive oxygen species (ROS) scavengers, transition 
metal chelators, nonsteroidal anti-inflammatory drugs, 
natural antioxidant polyphenols, anti-apoptotic drugs, 
and bioenergetic drugs in monotherapy or as part of 
an antioxidant cocktail formulation (Mandel, Youdim, 
2004).
The plant H. perforatum L. (Saint John’s wort) 
possesses anti-inflammatory, antioxidant, and nootropic 
properties (Rodríguez-Landa, Contreras, 2003; Griffith 
et al., 2010). Here, we investigated its effects on the 
nigrostriatal pathway lesion induced by unilateral 
injection of 6-hydroxydopamine (6-OHDA) into rats’ 
medial forebrain bundles, which led to partial retrograde 
degeneration of dopamine neurons in the substantia 
nigra. This model is widely used to investigate novel 
agents for relieving motor symptomsas well as potential 
neuroprotective compounds in PD (Blum et al., 2001).
MATERIAL AND METHODS
All procedures used in the present study were 
conducted according to national and international 
legislation, with approval of the Ethics Committee for 
Animal Research of the Universidade Estadual de Ponta 
Grossa (UEPG) (Process CEUA 14/2011/ Protocol 
UEPG-7821/2011). Subjects were adult male Wistar rats 
(3 months old, 280-340g) from the UEPG breeding stock. 
The animals were randomly divided into 8 groups (N= 
6-12): SHAM-vehicle, SHAM-HP100, SHAM-HP200, 
SHAM-HP400, 6-OHDA-vehicle, 6-OHDA-HP100, 
6-OHDA-HP200, and 6-OHDA-HP400.
Dry extract of aerial parts of H. perforatum (0.3% 
hypericin) (kindly donated by Laboratório Herbarium 
Botânico S/A, Colombo, Paraná, Brazil) was suspended 
in distilled water and administered by gavage (0, 100, 
200, or 400 mg/kg/ 2 ml/kg body weight). The control 
group received distilled water in the same volume. This 
administration happened once a day for 35 consecutive 
days (from 28 days before surgery to 7 days post-surgery).
On the surgery day, rats were anesthetized with 
thiopental (50 mg/kg, i.p.) and lesioned with 6-OHDA 
(Sigma-Aldrich Inc., St. Louis, MO, USA) (8 mg in 0.2% 
ascorbic acid 0.9% saline solution) on the left medial 
forebrain bundle following stereotaxic coordinates: 
anteroposteriorly -1.9 mm from the bregma; mediolaterally 
+1.9 mm from the midline; and dorsoventrally -7.9 mm 
from the skull (Paxinos, Watson, 1998; Da Cunha et al., 
2008).
The animals of the SHAM group received the 
vehicle solution (0.2% ascorbic acid in 0.9% saline 
solution). On the 7th, 14th, and 21st days after surgery, 
animals’ turning behavior was tested after administration 
of apomorphine (1mg/kg, s.c., Sigma-Aldrich). The 
number of 360º turns toward the lesioned (ipsilateral) 
or opposite side (contralateral) was recorded for 1h (Da 
Cunha et al., 2008).
At the 22nd day after surgery, the animals were 
decapitated, and their striata were collected and stored in a 
freezer at -80 ºC until analysis. Dopaminergic neuron death 
was quantified by tyrosine hydroxylase (TH) Western blot 
(Moreira et al., 2010). TH expression was compared 
between lesioned and contralateral sides. All values are 
expressed as means ± S.E.M. The statistical analysis was 
carried out using two–way analysis of variance (ANOVA). 
Following significant ANOVAs, post-hoc comparisons 
were performed using the Newman–Keuls test. The 
accepted level of significance for the tests was P≤ 0.05. 
All tests were performed using the Statistica® software 
package (StatSoft Inc., Tulsa, OK, USA).
RESULTS AND DISCUSSION
Figure 1 shows contralateral turns induced by 
apomorphine in hemiparkinsonian rats at 7 (Figure 1A), 
14 (Figure 1B), and 21 (Figure 1C) days after surgery. 
Two-way ANOVA indicated a significant effect of the 
lesion, since the 6-OHDA vehicle was different from the 
SHAM vehicle at the 7th [F (1,55) = 17.86, p<0.001], 14th 
[F (3,55) = 32.26, p< 0.001], and 21st days [F (3,55) = 
26.47, p< 0.001]. Regarding the H. perforatum treatment, 
all tested doses significantly reduced the number of turns 
induced by the 6-OHDA lesion on the 7th [F (3,55) = 8.73, 
p< 0.001], 14th [F (1,55) = 56.99, p< 0.001], and 21stdays 
[F (1,55) = 45.41, p< 0.001]. The interaction between the 
two factors was also similar for the 7th [F (3,55) = 10.35, 
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p< 0.001], 14th [F (3,55) = 36.37, p< 0.001], and 21stdays 
[F (3,55) = 28.67, p< 0.001].
The 6-OHDA-induced turning behavior observed in 
this work is in agreement with previous literature where 
severely unilaterally lesioned animals rotate toward the 
side contralateral to the lesion when challenged with 
apomorphine (a dopamine receptor agonist) (Figures 
1 A, B, and C). This rotation behavior occurs due to 
the imbalance of dopaminergic neurotransmission 
between injured and uninjured sides, so a larger lesion 
results in more rotations. This imbalance is caused by 
the overexpression of dopamine receptors in lesioned 
striatum, thus potentiating the apomorphine effect (Da 
Cunha et al., 2008, 2009).
Animals of SHAM groups treated with H. perforatum 
did not perform contralateral turns when challenged with 
apomorphine, indicating that the H. perforatum extract, 
or its withdrawal, did not affect rotational behavior. 
The reduced number of contralateral turns of 6-OHDA-
lesioned animals treated with H. perforatum could indicate 
a reduced neuronal loss when compared to the 6-OHDA 
group treated with the vehicle, but this hypothesis was not 
supported by the Western blot results.
Studies have shown that the administration of 
6-OHDA in laboratory animals’ brains leads to dopaminergic 
neuronal death and consequent reduced expression of TH 
in the striatum and substantia nigra, producing motor 
impairments similar to those observed in patients in the 
advanced stages of PD (Yin, Cao, Xie, 2010). Corroborating 
with these results, 6-OHDA induced a significant reduction 
of striatal TH levels (Figure 1D) compared to the SHAM-
vehicle group [F(1,16) = 186.42, p< 0.001]. Surprisingly, 
FIGURE 1 - Number of contralateral turns induced by apomorphine (1 mg/kg, s.c.) at 7 (A), 14 (B), and 21 (C) days after unilateral 
surgery with 6-OHDA in rats treated with different doses of extract of H. perforatum (100, 200, or 400 mg/kg) or vehicle for 35 days. 
Western blot of the TH expression in ipsilateral (D) and contralateral (E) to the lesion striata. N= 6-12 animals per group.***P < 0.001 
compared to SHAM + Vehicle group, ### P< 0.001 compared with the 6-OHDA-vehicle (two-way ANOVA followed by Newman-
Keuls post-hoc test).
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although able to reduce the contralateral rotations induced 
by apomorphine, the three tested doses of H. perforatum 
were not able to prevent the reduction in TH expression 
in the striatum ipsilateral to the lesion [F(3,16) = 0.10, 
p= 0.96]. Moreover, we did not observe any statistical 
differences among groups in the TH expression on the 
striatum contralateral to the lesion (Figure 1E), indicating 
a selective degeneration of dopaminergic neurons in the 
hemisphere injected with 6-OHDA.
Other authors have demonstrated that H. perforatum 
can block dopamine reuptake by presynaptic neurons 
(Calapai et al., 2001; Menini, Gobbi, 2004). This 
mechanism could explain the reduced number of rotations 
seen on the 7th day, but not on the 14th and 21st days after 
lesion, since the H. perforatum administration was only 
performed until the 7th post-lesion day. Moreover, a 
direct agonistic effect of H. perforatum on dopamine 
receptors at later periods (i.e., 14 and 21 days) following 
its administration is also improbable. 
One plausible hypothesis is that the H. perforatum 
may have hampered the overexpression of dopaminergic 
receptors on the lesioned side, which would have reduced 
the imbalance provoked by the 6-OHDA. Besides 
dopamine, H. perforatum also reduces serotonin and 
noradrenalin uptake, and it has been reported to have a 
brain-derived neurotrophic-factor-like effect (Leuner 
et al., 2007). Other authors indicate an interaction of 
hyperforin with non-dopaminergic receptors (Ikeda 
et al., 2012). Those effects in other structures, like the 
subthalamic nucleus, are involved on the modulation of 
turning behavior (Ikeda et al., 2012; Petri et al., 2013). 
Therefore, we propose that some of these mechanisms may 
have caused a long-term desensitization of the nigrostriatal 
synapses to the direct agonist apomorphine.
CONCLUSION
These results show for the first time that treatment 
with H. perforatum reduced the number of contralateral 
rotations in animals lesioned unilaterally with 6-OHDA 
and that these effects were not directly related with 
neuroprotective effects. These findings provide new 
evidence that H. perforatum may represent a promising 
therapeutic tool in PD, thus being able to prevent motor 
symptoms of PD. 
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